NDA 219164 · Ascendis
Yuviwel
Navepegritide · Subcutaneous
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Feb 27, 2026: To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 27, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
3 Phase 3, 1 recruiting
FAERS reports
5
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 25, 2026.
YUVIWEL ® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. ( 1 ) This indication is approved under accelerated approval based on an improvement in annualized growth velocity . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )
Mechanism: CNP released from navepegritide has the same receptor binding affinity and activity as endogenous CNP. CNP binds to natriuretic peptide receptor-B (NPR-B), which inhibits the mitogen activated protein kinase signaling (MAPK) pathway. Achondroplasia is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3) leading to overactive downstream signaling. The overly active FGFR3 inhibits endochondral ossification leading to short stature and skeletal dysplasia. Like endogenous CNP, CNP released from navepegritide binds to NPR-B, stimulating an increase in cyclic...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
3 products under this application
- YUVIWEL · NAVEPEGRITIDE 2.8MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- YUVIWEL · NAVEPEGRITIDE 5.5MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- YUVIWEL · NAVEPEGRITIDE 1.3MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Navepegritide" as an intervention, any sponsor and status, largest first.
- Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in AchondroplasiaPivotal-lookingNot yet recruiting
Ascendis Pharma A/SIndustry
NCT07924059 · 144 participants (planned) · Start Nov 2026 · Primary completion Sep 2028
Drug: Dual therapy with navepegritide and lonapegsomatropin; Dual therapy with navepegritide and placebo for lonapegsomatropin and 1 more · For: Achondroplasia
- A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With AchondroplasiaPivotal-lookingCompleted
Ascendis Pharma Growth Disorders A/SIndustry
NCT05598320 · 84 participants · Start Mar 3, 2023 · Primary completion Aug 9, 2024
Drug: Navepegritide (TransCon CNP); Placebo for Navepegritide (TransCon CNP) · For: Achondroplasia
Sites: Saint Paul, Minnesota; Columbia, Missouri; Houston, Texas · 10 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With HypochondroplasiaPivotal-lookingNot yet recruiting
Ascendis Pharma A/SIndustry
NCT07917143 · 81 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: Navepegritide; Placebo for Navepegritide · For: Hypochondroplasia
Ascendis Pharma A/SIndustry
NCT06079398 · 72 participants (planned) · Start Jan 23, 2024 · Primary completion Dec 2027
Drug: Navepegritide; Placebo for Navepegritide · For: Achondroplasia
Sites: Saint Paul, Minnesota; Houston, Texas; Madison, Wisconsin · 18 sites in all
Ascendis Pharma A/SIndustry
NCT04085523 · 57 participants · Start Jun 24, 2020 · Primary completion Sep 27, 2022
Drug: TransCon CNP; Placebo for TransCon CNP · For: Achondroplasia
Sites: Little Rock, Arkansas; Aurora, Colorado; Saint Paul, Minnesota · 15 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Active, not recruiting
Ascendis Pharma A/SIndustry
NCT06732895 · 25 participants · Start Dec 10, 2024 · Primary completion Sep 2027
Drug: Navepegritide; Placebo for navepegritide · For: Achondroplasia
Sites: Montreal, Canada; Copenhagen, Denmark; Paris, France · 5 sites in all
- A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaActive, not recruiting
Ascendis Pharma Growth Disorders A/SIndustry
NCT06433557 · 22 participants · Start Jul 26, 2024 · Primary completion Nov 14, 2025
Drug: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections · For: Achondroplasia
Sites: Copenhagen, Denmark; Dublin, Ireland; London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site reaction2
- needle issue2
- device difficult to use1
- hypoaesthesia1
- injury associated with device1
- paraesthesia oral1
- product administration error1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial.
Savarirayan R, McDonnell C, Bacino CA, et al. · JAMA Pediatr 2026 · Randomized Controlled Trial, Multicenter Study
- Assessing signs and impacts of achondroplasia: psychometric evaluation of the Achondroplasia Child Experience Measures.
Brod M, McLeod L, Smith A · J Patient Rep Outcomes 2026 · Multicenter Study, Observational Study
- Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial.
McDonnell CM, Irving M, Nolting LA, et al. · Eur J Endocrinol 2026 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Ascendis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.